Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma

Yuichiro Nakashima, Hiroshi Saeki, Qingjiang Hu, Yasuo Tsuda, Yuichi Hisamatsu, Kouji Andou, Eiji Oki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Aim: To confirm the superiority of neoadjuvant chemoradiotherapy (NACRT) over neoadjuvant chemotherapy (NAC) as preoperative therapy for locally advanced esophageal cancer. Patients and Methods: A total of 298 patients with resectable esophageal cancer were initially enrolled; 62 patients received NAC and 236 patients received NACRT. Propensity score matching was applied to create a study cohort. Results: Postoperative 30-day mortality rate, overall postoperative complication rate, and overall survival time did not differ between those groups. Complete pathological response occurred in one patient treated with NAC and 16 treated with NACRT (p<0.001). In patients with borderline-resectable T4 disease, overall survival was superior in the NACRT group compared to that in the NAC group (p=0.040). Conclusion: No survival advantage was observed between NAC and NACRT groups. Limited to patients with borderline-resectable T4, NACRT achieved a higher rate of primary tumor volume reduction and R0 resection, and a more favorable prognosis compared to NAC.

元の言語英語
ページ(範囲)6809-6814
ページ数6
ジャーナルAnticancer research
38
発行部数12
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Chemoradiotherapy
Drug Therapy
Esophageal Neoplasms
Propensity Score
Survival
Esophageal Squamous Cell Carcinoma
Tumor Burden
Cohort Studies
Survival Rate
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma. / Nakashima, Yuichiro; Saeki, Hiroshi; Hu, Qingjiang; Tsuda, Yasuo; Hisamatsu, Yuichi; Andou, Kouji; Oki, Eiji; Maehara, Yoshihiko.

:: Anticancer research, 巻 38, 番号 12, 01.12.2018, p. 6809-6814.

研究成果: ジャーナルへの寄稿記事

Nakashima, Yuichiro ; Saeki, Hiroshi ; Hu, Qingjiang ; Tsuda, Yasuo ; Hisamatsu, Yuichi ; Andou, Kouji ; Oki, Eiji ; Maehara, Yoshihiko. / Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma. :: Anticancer research. 2018 ; 巻 38, 番号 12. pp. 6809-6814.
@article{faef3de883d04ddb9be7470d8db1eec5,
title = "Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma",
abstract = "Aim: To confirm the superiority of neoadjuvant chemoradiotherapy (NACRT) over neoadjuvant chemotherapy (NAC) as preoperative therapy for locally advanced esophageal cancer. Patients and Methods: A total of 298 patients with resectable esophageal cancer were initially enrolled; 62 patients received NAC and 236 patients received NACRT. Propensity score matching was applied to create a study cohort. Results: Postoperative 30-day mortality rate, overall postoperative complication rate, and overall survival time did not differ between those groups. Complete pathological response occurred in one patient treated with NAC and 16 treated with NACRT (p<0.001). In patients with borderline-resectable T4 disease, overall survival was superior in the NACRT group compared to that in the NAC group (p=0.040). Conclusion: No survival advantage was observed between NAC and NACRT groups. Limited to patients with borderline-resectable T4, NACRT achieved a higher rate of primary tumor volume reduction and R0 resection, and a more favorable prognosis compared to NAC.",
author = "Yuichiro Nakashima and Hiroshi Saeki and Qingjiang Hu and Yasuo Tsuda and Yuichi Hisamatsu and Kouji Andou and Eiji Oki and Yoshihiko Maehara",
year = "2018",
month = "12",
day = "1",
doi = "10.21873/anticanres.13053",
language = "English",
volume = "38",
pages = "6809--6814",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy versus chemoradiotherapy for patients with esophageal squamous cell carcinoma

AU - Nakashima, Yuichiro

AU - Saeki, Hiroshi

AU - Hu, Qingjiang

AU - Tsuda, Yasuo

AU - Hisamatsu, Yuichi

AU - Andou, Kouji

AU - Oki, Eiji

AU - Maehara, Yoshihiko

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Aim: To confirm the superiority of neoadjuvant chemoradiotherapy (NACRT) over neoadjuvant chemotherapy (NAC) as preoperative therapy for locally advanced esophageal cancer. Patients and Methods: A total of 298 patients with resectable esophageal cancer were initially enrolled; 62 patients received NAC and 236 patients received NACRT. Propensity score matching was applied to create a study cohort. Results: Postoperative 30-day mortality rate, overall postoperative complication rate, and overall survival time did not differ between those groups. Complete pathological response occurred in one patient treated with NAC and 16 treated with NACRT (p<0.001). In patients with borderline-resectable T4 disease, overall survival was superior in the NACRT group compared to that in the NAC group (p=0.040). Conclusion: No survival advantage was observed between NAC and NACRT groups. Limited to patients with borderline-resectable T4, NACRT achieved a higher rate of primary tumor volume reduction and R0 resection, and a more favorable prognosis compared to NAC.

AB - Aim: To confirm the superiority of neoadjuvant chemoradiotherapy (NACRT) over neoadjuvant chemotherapy (NAC) as preoperative therapy for locally advanced esophageal cancer. Patients and Methods: A total of 298 patients with resectable esophageal cancer were initially enrolled; 62 patients received NAC and 236 patients received NACRT. Propensity score matching was applied to create a study cohort. Results: Postoperative 30-day mortality rate, overall postoperative complication rate, and overall survival time did not differ between those groups. Complete pathological response occurred in one patient treated with NAC and 16 treated with NACRT (p<0.001). In patients with borderline-resectable T4 disease, overall survival was superior in the NACRT group compared to that in the NAC group (p=0.040). Conclusion: No survival advantage was observed between NAC and NACRT groups. Limited to patients with borderline-resectable T4, NACRT achieved a higher rate of primary tumor volume reduction and R0 resection, and a more favorable prognosis compared to NAC.

UR - http://www.scopus.com/inward/record.url?scp=85057532425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057532425&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13053

DO - 10.21873/anticanres.13053

M3 - Article

C2 - 30504394

AN - SCOPUS:85057532425

VL - 38

SP - 6809

EP - 6814

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -